![Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial - The Lancet Gastroenterology & Hepatology Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/00312b86-330c-4d9b-9e07-981f7e10a581/gr1.gif)
Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial - The Lancet Gastroenterology & Hepatology
![Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Science Translational Medicine Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Science Translational Medicine](https://www.science.org/cms/10.1126/scitranslmed.aaf6219/asset/c92e21f9-c409-4d11-bfc7-3956d7aa8ef8/assets/graphic/8-346ra92-f1.jpeg)
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Science Translational Medicine
![The prognostic significance of apical lymph node metastasis in patients with high-risk stage III colon cancer | Scientific Reports The prognostic significance of apical lymph node metastasis in patients with high-risk stage III colon cancer | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-06054-5/MediaObjects/41598_2022_6054_Fig1_HTML.png)
The prognostic significance of apical lymph node metastasis in patients with high-risk stage III colon cancer | Scientific Reports
![Recurrence Outcomes Less Favorable in T1 Rectal Cancer than in T1 Colon Cancer - Chang - 2021 - The Oncologist - Wiley Online Library Recurrence Outcomes Less Favorable in T1 Rectal Cancer than in T1 Colon Cancer - Chang - 2021 - The Oncologist - Wiley Online Library](https://theoncologist.onlinelibrary.wiley.com/cms/asset/c489f76b-8a00-4c3f-ad84-8bff6e2c0ecf/onco13815-fig-0003-m.jpg)
Recurrence Outcomes Less Favorable in T1 Rectal Cancer than in T1 Colon Cancer - Chang - 2021 - The Oncologist - Wiley Online Library
![Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes - ScienceDirect Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0016508514012013-gr3.jpg)
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes - ScienceDirect
![Prevention of Colon Cancer Recurrence From Minimal Residual Disease: Computer Optimized Dose Schedules of Intermittent Apoptotic Adjuvant Therapy | JCO Clinical Cancer Informatics Prevention of Colon Cancer Recurrence From Minimal Residual Disease: Computer Optimized Dose Schedules of Intermittent Apoptotic Adjuvant Therapy | JCO Clinical Cancer Informatics](https://ascopubs.org/cms/10.1200/CCI.20.00016/asset/images/large/cci.20.00016f3.jpeg)
Prevention of Colon Cancer Recurrence From Minimal Residual Disease: Computer Optimized Dose Schedules of Intermittent Apoptotic Adjuvant Therapy | JCO Clinical Cancer Informatics
![Advanced Age Is a Risk Factor for Recurrence After Resection in Stage II Colorectal Cancer | In Vivo Advanced Age Is a Risk Factor for Recurrence After Resection in Stage II Colorectal Cancer | In Vivo](https://iv.iiarjournals.org/content/invivo/34/1/339/F1.large.jpg)
Advanced Age Is a Risk Factor for Recurrence After Resection in Stage II Colorectal Cancer | In Vivo
![Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer | International Journal of Clinical Oncology Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer | International Journal of Clinical Oncology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10147-019-01485-z/MediaObjects/10147_2019_1485_Fig9_HTML.png)
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer | International Journal of Clinical Oncology
![PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/924dcf6ba539d31ea808e6e522d135081883cc9e/4-Figure2-1.png)
PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar
![PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/924dcf6ba539d31ea808e6e522d135081883cc9e/2-Figure1-1.png)
PDF] High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population | Semantic Scholar
![Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies - ScienceDirect Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419459954-gr1.jpg)
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies - ScienceDirect
![Pelvic local recurrence as first relapse predicts prognosis for clinical stage II/III lower rectal cancer: A clinicopathological investigation Pelvic local recurrence as first relapse predicts prognosis for clinical stage II/III lower rectal cancer: A clinicopathological investigation](https://www.spandidos-publications.com/article_images/mco/14/2/mco-14-02-02195-g02.jpg)
Pelvic local recurrence as first relapse predicts prognosis for clinical stage II/III lower rectal cancer: A clinicopathological investigation
![Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings | World Journal of Surgical Oncology | Full Text Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings | World Journal of Surgical Oncology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2F1477-7819-12-145/MediaObjects/12957_2014_Article_1631_Fig1_HTML.jpg)
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings | World Journal of Surgical Oncology | Full Text
![Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials](https://www.jcancer.org/ms/getimage.php?name=jcav08p4057g002.jpg)
Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials
![Cancers | Free Full-Text | Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It? Cancers | Free Full-Text | Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?](https://www.mdpi.com/cancers/cancers-12-03308/article_deploy/html/images/cancers-12-03308-g001.png)
Cancers | Free Full-Text | Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?
![Long-term outcomes after complete mesocolic excision for colon cancer at a tertiary care center in Saudi Arabia | Annals of Saudi Medicine Long-term outcomes after complete mesocolic excision for colon cancer at a tertiary care center in Saudi Arabia | Annals of Saudi Medicine](https://www.annsaudimed.net/cms/asset/f3b90a8b-897d-4dba-8590-6c14fe59bf83/asm-3-207.jpg)